IGC Trials Research Effective THC Drug Dosing For Alzheimer's Patients

India Globalization Capital, Inc. (AMEX: IGC) revealed the preliminary results of its exploratory endpoints from a Phase 1 clinical trial of a THC-drug to treat Alzheimer’s symptoms.

The Phase 1 clinical trial provided valuable insights on Pharmacokinetics (PK) and genotyping that will be essential in determining optimal dosing when moving into subsequent trials, subject to U.S. Food and Drug Administration (FDA) approval.

The THC-drug or IGC-AD1 is a proprietary cannabis-based investigational new drug candidate for patients suffering from Alzheimer's, which impacts about 50 million people worldwide, approximately 66% of whom are women. Unfortunately, there is no cure for Alzheimer’s and no -approved pharmaceuticals to treat the many unpleasant symptoms, including agitation.

Clinical Trial Details

Pharmacokinetics studies how long it takes for the body …

Full story available on Benzinga.com

More IGC Trials Research Effective THC Drug Dosing For Alzheimer's Patients